BRPI0416492A - forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória - Google Patents

forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória

Info

Publication number
BRPI0416492A
BRPI0416492A BRPI0416492-0A BRPI0416492A BRPI0416492A BR PI0416492 A BRPI0416492 A BR PI0416492A BR PI0416492 A BRPI0416492 A BR PI0416492A BR PI0416492 A BRPI0416492 A BR PI0416492A
Authority
BR
Brazil
Prior art keywords
substance
active ingredient
influences
matrix
distribution
Prior art date
Application number
BRPI0416492-0A
Other languages
English (en)
Inventor
Rosario Lizio
Hans-Ulrich Petereit
Manfred Assmus
Hema Ravishankar
Original Assignee
R Hm Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Hm Gmbh & Co Kg filed Critical R Hm Gmbh & Co Kg
Publication of BRPI0416492A publication Critical patent/BRPI0416492A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMA FARMACêUTICA MULTICAMADAS COM UMA MATRIZ A QUAL INFLUENCIA A DISTRIBUIçãO DE UMA SUBSTáNCIA MODULATóRIA". A presente invenção refere-se a uma forma farmacêutica de múltiplas camadas para liberação controlada de ingrediente ativo, essencialmente compreendendo: a) Opcionalmente um núcleo neutro (não-análogo), b) Uma camada de controle interna compreendendo uma substância com um efeito modulador, a qual está embebida numa matriz a qual influencia a distribuição da substância modulatória e a qual compreende polímeros, ceras, resinas e/ou proteínas farmaceuticamente usáveis, e onde apropriado um ingrediente ativo, c) Uma camada de ingrediente ativo compreendendo um ingrediente farmaceuticamente ativo e, onde apropriado, uma substância com um efeito modulador, d) Uma camada de controle externa compreendendo pelo menos 60% em peso de uma ou uma mistura de uma pluralidade de copolímeros de (met)acrilato composta de 98 a 85 de ésteres de ácido (met)acrílico de alquiIa C~ 1~ a C~ 4~ e de 2 a 15% em peso de monómeros de metacrilato com um grupo quaternário de amónio no radical alquila e, onde apropriado, polímeros adicionais farmaceuticamente usáveis insolúveis em água, onde as camadas podem adicionalmente e de uma forma conhecida per se compreender excipientes farmaceuticamente usuais.
BRPI0416492-0A 2003-11-13 2004-09-15 forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória BRPI0416492A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10353196A DE10353196A1 (de) 2003-11-13 2003-11-13 Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
PCT/EP2004/010300 WO2005046561A2 (de) 2003-11-13 2004-09-15 Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix

Publications (1)

Publication Number Publication Date
BRPI0416492A true BRPI0416492A (pt) 2007-03-13

Family

ID=34585091

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416492-0A BRPI0416492A (pt) 2003-11-13 2004-09-15 forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória

Country Status (10)

Country Link
US (1) US20070042045A1 (pt)
EP (1) EP1682094A2 (pt)
JP (1) JP2007510677A (pt)
KR (1) KR20060113728A (pt)
CN (1) CN1863516A (pt)
BR (1) BRPI0416492A (pt)
CA (1) CA2544487A1 (pt)
DE (1) DE10353196A1 (pt)
IL (1) IL175562A0 (pt)
WO (1) WO2005046561A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522146A (ja) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． 外圧に抵抗性の経口オピオイドアゴニスト製剤
AU2003270778B2 (en) * 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
CN101111231A (zh) * 2005-03-29 2008-01-23 罗姆有限公司 包含具有影响调节物质递送的基质的小丸的多颗粒药用形式
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
KR101320016B1 (ko) * 2005-12-14 2013-10-29 주식회사 대웅 안정화된 코엔자임ｑ10, 종합 비타민 및 미네랄 성분을함유하는 복합제제
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
PT2034975E (pt) * 2006-06-19 2012-06-25 Alpharma Pharmaceuticals Llc Composições farmacêuticas
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101652141A (zh) * 2007-03-29 2010-02-17 万能药生物有限公司 他克莫司的调节释放剂型
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR101571179B1 (ko) * 2008-01-10 2015-11-23 에보니크 룀 게엠베하 증가된 맥동성 활성 물질 방출을 갖는 코팅된 제약학적 또는 건강기능성 제제
BRPI0821985A2 (pt) * 2008-01-10 2015-06-23 Evonik Roehm Gmbh Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada
SI2230932T1 (sl) * 2008-01-10 2017-07-31 Evonik Roehm Gmbh Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
WO2010096732A1 (en) * 2009-02-20 2010-08-26 University Of Medicine And Dentistry Of New Jersey Combination therapy to improve drug efficiency
KR101317592B1 (ko) 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
KR101137467B1 (ko) * 2009-11-02 2012-04-20 안국약품 주식회사 테오브로민 함유 서방성 정제
WO2011107855A2 (en) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
JP2013534145A (ja) * 2010-08-18 2013-09-02 クラフト・フーズ・グローバル・ブランズ・エルエルシー 口内湿潤化ガム組成物およびそれを含む製品
KR101220830B1 (ko) * 2010-08-18 2013-01-10 안국약품 주식회사 테오브로민의 서방성 과립제 및 그 제조방법
SG191872A1 (en) 2011-02-02 2013-08-30 Alpharma Pharmaceuticals Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR101659983B1 (ko) 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
ES2926192T3 (es) 2017-07-07 2022-10-24 Dsm Ip Assets Bv Tabletas comprimidas que comprenden nitrooxicompuestos
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483335D1 (de) * 1983-03-18 1990-11-08 Matsushita Electric Ind Co Ltd Videosignalverarbeitungseinrichtung fuer videobandaufzeichnungsgeraete.
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
JP3426230B2 (ja) * 1991-05-20 2003-07-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド 複数層の制御放出処方剤
JPH04360826A (ja) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform

Also Published As

Publication number Publication date
WO2005046561A2 (de) 2005-05-26
CN1863516A (zh) 2006-11-15
DE10353196A1 (de) 2005-06-16
WO2005046561A3 (de) 2006-03-16
JP2007510677A (ja) 2007-04-26
IL175562A0 (en) 2008-04-13
KR20060113728A (ko) 2006-11-02
EP1682094A2 (de) 2006-07-26
US20070042045A1 (en) 2007-02-22
CA2544487A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0416492A (pt) forma farmacêutica multicamadas com uma matriz a qual influencia a distribuição de uma substáncia modulatória
WO2005046649A3 (de) Mehrschichtige arzneiform, enthaltend eine in bezug auf die wirkstoffreigabe modularisch wirkende substanz
Wang et al. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice
WO2000019984A3 (de) Überzogene arzneiformen mit kontrollierter wirkstoffabgabe
DE50310448D1 (de) Mehrschichtige wirkstoffhaltige arzneiformen, die einen neutralen kern sowie einen inneren und äusseren überzug aus methacrylat-copolymeren und -monomeren umfassen
Shenoda The role of Na+/Ca 2+ exchanger subtypes in neuronal ischemic injury
Kaur et al. Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson’s disease in rats
BR0210971A (pt) Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas
DE602005008460D1 (de) Zusammensetzung mit verzögerter arzneimittelfreisetzung mit einem aufsteigenden nullordnung-freigabe-muster; verfahren zur herstellung einer solchen zusammensetzung"
BRPI0716439B8 (pt) sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
Shimoke et al. Involvement of phosphatidylinositol-3 kinase in prevention of low K+-induced apoptosis of cerebellar granule neurons
Brissette et al. Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis
HRP20130115T4 (hr) Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata
MX356579B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
Cui et al. Sulbactam plays neuronal protective effect against brain ischemia via upregulating GLT1 in rats
Wang et al. Dopamine in the hippocampal dentate gyrus modulates spatial learning via D1-like receptors
Grahn et al. Blockade of alpha1 adrenoreceptors in the dorsal raphe nucleus prevents enhanced conditioned fear and impaired escape performance following uncontrollable stressor exposure in rats
RU2010139906A (ru) Способ обеспечения требуемых уровней фактора 2 роста глии в плазме
BR0107262C1 (pt) Composição a base de monoterpenos, com efeito, quimiopreventivo e quimioterápico em neoplasias malignas de seres humanos e animais, utilização dos monoterpenos na inbição do crescimento de células tumorais e no controle de metástases de tumores primários e método especìfico de utilização da composição, com efeito, quimiopreventivo e quimioterápico em seres humanos e animais
BR0117149A (pt) Uso de um copolìmero para produzir uma forma farmacêutica contendo um peptìdio ou proteìna como agente ativo
Koyama et al. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes
Takuma et al. T-588 inhibits astrocyte apoptosis via mitogen-activated protein kinase signal pathway
PE20001496A1 (es) Formulacion de liberacion controlada para el tratamiento de epoc
BRPI0822140A8 (pt) Preparação farmacêutica ou nutracêutica revestida tendo liberação pulsada de subsatância ativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.